Gilead's Stribild price threatened by German snub
This article was originally published in Scrip
Executive Summary
Germany has issued a preliminary finding that Gilead Sciences' new four-in-one HIV pill Stribild does not offer a benefit over its older fixed-dose combination product, Atripla.